Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs 9amHealth

Two GLP-1 providers, one scoreboard. We put CoreAge Rx and 9amHealth head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 386 · Grade C

9amHealth

Visit 9amHealth Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 58 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.

That doesn't make 9amHealth a bad call — it's best for people managing weight alongside metabolic conditions who want ongoing clinical and nutrition support and help navigating drug coverage. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
44
Supply Reliability
95
80
Transparency
90
24
Access Breadth
93
46
Clinical Oversight
92
92
Track Record
88
80
CoreAge RxBrief Score 94 · 589amHealth

Price, coverage & the tracker

CoreAge Rx9amHealth
Brief Score94/100 (A)58/100 (C)
Semaglutide

From $79/mo

Annual offer: 12 months paid upfront, from $948.

Main site: from $99/mo; confirm the selected offer.

Full price details

From $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo

Wegovy: current full quote unconfirmed

Named branded option in an ongoing care program. Membership and selected medication costs depend on the actual clinical/coverage agreement.

Prescription and coverage are not guaranteed. Confirm pharmacy/device, laboratory costs, treatment-state eligibility and membership/refill cancellation terms.

Full price details

Named Wegovy care advertised; complete current semaglutide medication and membership quote unknown; product selection and coverage depend on clinical and insurance review

Tirzepatide

From $129/mo

Annual offer: 12 months paid upfront, from $1,548.

Main site: from $149/mo; confirm the selected offer.

Full price details

From $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo

Zepbound: current full quote unconfirmed

Named branded option in an ongoing care program. Membership and selected medication costs depend on the actual clinical/coverage agreement.

Prescription and coverage are not guaranteed. Confirm pharmacy/device, laboratory costs, treatment-state eligibility and membership/refill cancellation terms.

Full price details

Named Zepbound care advertised; complete current tirzepatide medication and membership quote unknown; autoinjector and vial options described with different out-of-pocket considerations

CoverageUS only; restrictions by state, confirmed at intakeActual treatment-state eligibility requires confirmation; reviewed individual-care pages do not establish an unconditional nationwide medication offer
Brand-name accessNot confirmedYes
Oral / sublingualInjection onlyUnconfirmed
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.

9amHealth: Named branded weight-care options with ongoing membership; complete care/drug quote unconfirmed. Confirm coverage, Zepbound device, pharmacy payment and separate membership/refill cancellation rules.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.